Zydus and Sun Pharma sign licensing agreement for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in India

Ahmedabad : Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) have announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India. Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket the product in India. Sun Pharma will market the drug under the brand name RYTSTAT®. Zydus launched the drug under the brand name Oxemia™ in 2022 and will continue to market it. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones.

A spokesperson from Zydus Lifesciences Ltd. said, “Our life changing discoveries are guided by the need to help patients and empower them with therapies that enable them to live healthier and more fulfilled lives. Desidustat which is one of the critical treatment options for CKD patients has substantially improved the patients’ quality of life since it is more convenient to take an oral pill instead of an injection that needs to be administered. We are pleased to join hands with Sun Pharma to expand the reach of this novel medicine by enabling access to more patients.”